Specialty Focus Target i3 Pharmaceuticals for high-value, difficult-to-formulate solid oral specialty products where customers require advanced formulation and manufacturing capabilities and high technical barriers.

Small to Mid Cap Growth Leverage their modest size (11-50 employees) and mid-range revenue to position as a trusted partner for scalable manufacturing collaborations, white-labeling opportunities, or toll manufacturing agreements with larger biopharma players seeking niche capabilities.

Quality and Compliance Align sales pitches with their core commitment to product quality and integrity in partnerships, emphasizing GMP-compliant manufacturing, quality systems, and end-to-end supply chain reliability to attract customers seeking robust risk management.

Tech-EnabledOps Highlight potential for technology-enabled manufacturing and data-driven operations by offering digital collaboration tools, integrated analytics, and scalable IT infrastructure support that complements their existing tech stack.

Funding Readiness Approach as a partner capable of accelerating market access for novel solid oral specialty products, positioning co-development, capital-efficient manufacturing, and strategic funding discussions aligned with their current revenue and $16M funding.